Modern data about features of adrenoreceptors (AR) and adrenoblockers (AB) classification, adrenomimetic drugs (agonists) and the AB action mechanism, implementation of the physiological effects of adrenergic structures are represented in this article. It is generally accepted that the implementation of adaptive adrenergic effects is associated with the state and functional characteristic of adrenoreactive structures dominant population. They are able to modify certain physiological and biochemical processes through the appropriate second messenger system. Considering this, an important problem of modern physiology and medicine is to establish the implementation mechanism and characteristics of the physiological effects of AB in various organs and systems. That is why it is important to clarify the possibilities for optimizing or stimulation of compensatory physiological processes by modulating the adrenergic effects.

Modern classification of AR is based on the features of their sensitivity to the pharmacological agents – agonists and blockers, and also depends on the location, physical and biological properties of adrenergic structures. Consequently there are distinguished – α1- and α2- and ß1-, ß2, ß3-AR, also pre-, post- and extra-synaptic adrenergic receptors. The attention is focused on the fact, that understanding of signal pathways implementation effects of biologically active substances or mechanisms of signal transduction gives a holistic view on the appropriate phased effects of adrenergic hormone-receptive interaction. Typically, such combination is formed with the involvement of proteins that bind guanine nucleotides – connecting G-proteins, which identifies the name of the receptors – GPCR-receptors.

It became apparent that the transmission of neural information in the autonomic nervous system (ANS) can be carried out without adrenergic or cholinergic reactions, in addition, a lot of synapses use much more than one neurotransmitter. This co-transmission, as it is known now, is common in ANS.

The authors presented the results of their research on protective modulative effects of AB in the post hypoxia adaptation of various organs and systems. In particular, it was found that prior to the introduction of hypoxia action administration of α-AB – doxazosin accompanies optimization of structural and functional alterations in small intestine mucous membrane tissue mitochondria. At the same time, unselective ß-AB – propranolol application under similar conditions, significantly, improves both mitochondria structural and functional indicators of liver tissue. Judging by changes in heart rate variability applying propranolol improves course of adaptive reactions in these conditions at the level of the whole organism.

The authors own observations and literature review suggest that modern understanding of adrenergic system regulatory effects implementation must provide, in addition to generally accepted traditional mechanisms, the involvement of non-traditional signaling chains, co-mediator system. It generally can significantly extend the adaptive organism capabilities and affect the quality stress reaction remodulation. Considering these characteristics providing rational approach to the administration of agonists and AB, will improve the efficiency of medical tactics, reduce the risk of manifestation of side effects. However, the use of these drugs may be appropriate model for a deep studying the mechanisms of nonspecific adaptation syndrome by various extreme effects.

Article Received 11.08.2016

Ключові слова: adrenoreceptors, adrenoblockers, hypoxia, adaptation, signal pathways

Повний текст: PDF (Ukr)

1. 1. Pishak V, Kryvchanska M, Pishak O, Hrytsyuk M. Beta-blockers: classification, mechanisms of action. Medical possibilities. 2011;11:25-30.
2. 2. Matyushin A. Adrenergic receptors of heart. Pharmacology and toxicology. 1986;1:107-113.
3. 3. Davydova I. Beta-adrenoblockers: mechanisms of action, classification, indications and contraindications. Cardiology. 2009;60(4):70-78.
4. 4. Lysenko H, Yaschenko O. Drug treatment of patients with hypertension. Ukrainian Medical Journal. 2011;3:83-91.
5. 5. Berezin A. The efficacy and safety of chronic beta-adrenoblockade in high cardiovascular risk patients. Ukr. med. magazine. 2008;2:35-41.
6. 6. Afanasyeva D, Chykalova I. Beta-BLOCKERS in diabetes mellitus – Balance of properties, concerns, risks and tasks. Ukr. med. magazine. 2007;6:48-56.
7. 7. Ogol A. Adverse effects of beta-blockers: notions and reality. Ukr. Med. magazine. 2009;4:14-22.
8. 8. Dementieva N, Dihtyar V, Smooth O, Avilov O, Kolomiyets' O, Ashkinazi B et al. The use of propranolol in the treatment of hemangiomas in childrenwith complex localizations. Clinical Oncology. 2011;4:10-16.
9. 9. Rudyk Y. Heart failure and pharmacogenetic: Focus – beta-blockers. Ukrainian therapeutic magazine. 2010;1:49-59.
10. 10. Gzhehotskyy M, Furdychko L, Terletska O et al. Structural and metabolic parameters of liver and small intestinal mucosa of rats under the influence of radiation on the background of the introduction blocker. Practical Medicine. 2008;6:47-51.
11. 11. Trefilov A. Effect of prednisone on the basal secretion of gastric laboratory rats, depending on the functional state of the stomach adrenoceptor. Russian physiological log them. Sechenov. 2002;88(4):519-525.
12. 12. Kharchenko V, Aslanyan A, Ashimov I. The use of blockers to correct lung function in the treatment of acute cholecystitis. Clinical medicine. 1989;11:50-52.
13. 13. Sheverova V. Neurophysiological effects of β-blocker obzidan simulation under conditions of emotional stress. Physiol. Zh. 1997;43(1-2):31-40.
14. 14. Terletska O, Kovalchuk S, Shalko O. Post hypoxia changes in adaptation mechanisms during previous use of alpha-blockers. Mod. quest. of medical science. 2014;1:117.
15. 15. Zvyahyntseva T, Hamanenko N. Correction lypydov peroxidation and protection of antioxidant in patients with chronic stomach ulcer. Modern Gastroenterology. 2014;1:117.
16. 16. Romaniuk S, Komisarenko S. Stem cells and receptors associated with G-proteins – again at the forefront of science. Ukr. Biochem. Mag. 2013;85(1):96-106. doi.org/10.15407/ubj85.01.096
17. 17. Drobot L, Samoylenko A, Vorotnikov A, Tyurin-Kuzmin P, Bazalii A, Kietzmann T et al. Reactive oxygen species in signal transduction. Укр. біохім. журн. 2013;85(6):208-216.
18. 18. Qian B, Danielsson A, el-Salhy M. Vagal regulation of the gastrointestinal neuroendocrine system. J Gastroenterology. 1996;31:529-540. doi.org/10.3109/00365529609009124
19. 19. Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S et al. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive. Type 2 diabetic patients with overt nephropathy. Diabet Med. 2005;22(1):1394-1400. doi.org/10.1111/j.1464-5491.2005.01636.x
20. 20. Gyires K, Zadori S, Torok T, Matyus P, Egyetem S, Egyetem P. alpha2-adrenoreceptor subtypes-mediated physiological, pharmacological actions. Neurochem. Int. 2009;55(7):447-453. oi.org/10.1016/j.neuint.2009.05.014
21. 21. Zadori S, Shujaa N, Brancati S, Hein L, Gyires K. Both α2B- and α2C-adrenoceptor subtypes are involved in the mediation of centrally induced gastroprotection in mice. Eur. J. Pharmacol. 2011;669(1):115-120. doi.org/10.1016/j.ejphar.2011.07.018
22. 22. Guicheney P, Meyer P. Binding of [3H]-Prazozin and [3H]-dihydroergotriptine to rat cardiac α-adrenoreceptors. Brit. J. Pharmacol. 1981;73(1):33-39. doi.org/10.1111/j.1476-5381.1981.tb16768.x
23. 23. Williams R, Lefkowitz R. Demonstration of α-adrenoreceptors in the rabbit heart by [3H]-dihydroergocryptine binding. Circulat.Res. 1978;43:721-727. doi.org/10.1161/01.RES.43.5.721
24. 24. Kasacka I, Majevski M. Doxazosin inhibition of the hypertension-induced changes of endocrine cells in the stomach of spontaneously hypertensive rats. Journal of phisiology and pharmacology. 2008;59(1):189-201.
25. 25. Pischon T, Sharma M. Use of beta- blockers in obesity hypertension: potential role of weight gain. Obesity reviews. 2001;2:275-280. doi.org/10.1046/j.1467-789X.2001.00044.x
26. 26. Enjolras O, Brevière G, Roger G, Tovi M, Pellegrino B, Varotti E et al. Vincristine treatment for function and life-threatening infantile hemangioma. Arch. Pediatr. 2004;11:99-107. doi.org/10.1016/j.arcped.2003.10.014
27. 27. Takahisa N, Lemaire A, Prasad S, Barki-Harrington L, Tilley D, Chen J et al. Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. Journal of Clinical Investigation. 2007;117(9):2445-2458. doi.org/10.1172/JCI31901
28. 28. Trester-Zedlitz M, Burlingame A, Kobilka B. Mass spectrometric analysis of agonist effects on posttranslational modifications of the β2-adrenoceptor in mammalian cells. Biochemistry. 2005;44:6133-6143. doi.org/10.1021/bi0475469
29. 29. Baameur F, Moore R, Clark R. Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the β2-adrenergic receptor using phosphoserine-specific antibodies. Mol. Pharmacol. 2004;65:196-206. doi.org/10.1124/mol.65.1.196
30. 30. Lorton D, Bellinger L. Molecular mechanisms underlying β-Adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells. Int. J. Mol. Sci. 2015;16:5635-5665. Véronique Sans, Eric Dumas de la Roque, Jérôme Berge, Dan Lipsker, Elisabeth Dupuis, Khaled Ezzedine, Pierre Vergnes, Alain Taïeb, Christine Léauté-Labrèze doi.org/10.3390/ijms16035635
31. 31. Lohse M, Benovic J, Codina J. Beta-arrestin: A protein that regulates β-adrenergic receptor function. Science. 1990;248:1547-1550. doi.org/10.1126/science.2163110
32. 32. Sans V, Roque E, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):423-431. doi.org/10.1542/peds.2008-3458
33. 33. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001;44(3):195-208. doi.org/10.1006/phrs.2001.0857
34. 34. Bangalore S, Messerli F. Hypertension in the elderly: a compelling contraindication for β-blockers. Journal of Human Hypertension. 2007;21:259-260. doi.org/10.1038/sj.jhh.1002144
35. 35. Engelhardt S. Alternative signaling: cardiomyocyte β1-adrenergic receptors signal through EGFRs. Journal of Clinical Investigation. 2007;117: 2396-2398. doi.org/10.1172/JCI33135
36. 36. Dennis R. Adrenergic and noradrenergic regulation of poultry behavior and production. Domestic Animal Endocrinology. 2016;56:94-100. doi.org/10.1016/j.domaniend.2016.02.007
37. 37. Kunde S, Rademacher N, Tzschach A, Wiedersberg E, Ullmann R, Kalscheuer V et al. Characterisation of de novo MAPK10/JNK3 truncation emutations associated with cognitive disorders in two unrelated patients. Hum. Genet. 2013;132:461-471. doi.org/10.1007/s00439-012-1260-5
38. 38. Mustafa A, Gazi S. Neurotransmitters. Reference Module in Biomedical Sciences. 2014;2:565-572.
39. 39. Donny Strosberg A. UK: CRC Press; 2013. 192.
40. 40. Banares R, Moitinho E, Piqueras B. Carvediolol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 2000;31(3):809-811.
41. 41. Kanner J, Harel S, Granit R. Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids. 1992;1:46-49. doi.org/10.1007/BF02537058
42. 42. Bangalore S, Messerli F, Kostis J, Pepine C. Cardiovascular protection using beta-blockers: a critical review of the evidence. J. Amer. Coll. Cardiology. 2007;50(7):563-572. doi.org/10.1016/j.jacc.2007.04.060
43. 43. Gzhegotsky M, Furdichko L, Kovalchuk S et al. Estimation of adaptation reserve of the organism functional systems under ionizing radiation and previous introduction of propranolol adrenoblocker. Advances in Pharmacology and Phatology. 2012;1:42.